We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Harrow Inc | NASDAQ:HROW | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.66 | -2.04% | 31.69 | 30.11 | 34.28 | 33.14 | 31.5001 | 32.83 | 280,057 | 01:00:00 |
From Jan 2024 to Jan 2025
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 14, 2024, to discuss the results and provide a business update.
Conference Call Details:
Date:
Tuesday, May 14, 2024
Time:
8:00 a.m. Eastern time
Participant Dial-in:
1-833-953-2434 (U.S.) 1-412-317-5763 (International)
Replay Dial-in (Passcode 3093849):
(telephonic replay through May 21, 2024)
1-877-344-7529 (U.S.) 1-412-317-0088 (International)
Webcast: (online replay through May 14, 2025)
harrow.com
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425737701/en/
Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com 615-733-4737
1 Year Harrow Chart |
1 Month Harrow Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
